These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3316499)

  • 21. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in regional brain atrophy in genetic forms of Alzheimer's disease.
    Gregory GC; Macdonald V; Schofield PR; Kril JJ; Halliday GM
    Neurobiol Aging; 2006 Mar; 27(3):387-93. PubMed ID: 15894410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuropathological changes associated with normal brain aging.
    Hof PR; Glannakopoulos P; Bouras C
    Histol Histopathol; 1996 Oct; 11(4):1075-88. PubMed ID: 8930649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Changes in the neuronal size in the brain by aging and of Alzheimer's dementia].
    Tomonaga M
    No To Shinkei; 1988 Jan; 40(1):57-64. PubMed ID: 3282529
    [No Abstract]   [Full Text] [Related]  

  • 25. Spatial patterns of mammalian brain aging: distribution of cathepsin D-immunoreactive cell bodies and dystrophic dendrites in aging dogs resembles that in Alzheimer's disease.
    Bi X; Head E; Cotman CW; Lynch G
    J Comp Neurol; 2003 Sep; 464(3):371-81. PubMed ID: 12900930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review.
    Ringman JM
    J Geriatr Psychiatry Neurol; 2005 Dec; 18(4):228-33. PubMed ID: 16306245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
    Kantarci K
    Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease.
    Miatto O; Gonzalez RG; Buonanno F; Growdon JH
    Can J Neurol Sci; 1986 Nov; 13(4 Suppl):535-9. PubMed ID: 3791069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia.
    Brown GG; Levine SR; Gorell JM; Pettegrew JW; Gdowski JW; Bueri JA; Helpern JA; Welch KM
    Neurology; 1989 Nov; 39(11):1423-7. PubMed ID: 2812317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aging of the brain, Alzheimer's disease and the most frequent vascular dementias].
    Koukolík F
    Cesk Neurol Neurochir; 1990 Jan; 53(1):1-11. PubMed ID: 2185896
    [No Abstract]   [Full Text] [Related]  

  • 31. Structural neuroimaging in aging and Alzheimer's disease.
    Vernooij MW; Smits M
    Neuroimaging Clin N Am; 2012 Feb; 22(1):33-55, vii-viii. PubMed ID: 22284732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease.
    Pettegrew JW; Panchalingam K; Moossy J; Martinez J; Rao G; Boller F
    Arch Neurol; 1988 Oct; 45(10):1093-6. PubMed ID: 3178529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between 31P NMR phosphomonoester and biochemically determined phosphorylethanolamine and phosphatidylethanolamine during development of the rat brain.
    Burri R; Lazeyras F; Aue WP; Straehl P; Bigler P; Althaus U; Herschkowitz N
    Dev Neurosci; 1988; 10(4):213-21. PubMed ID: 3224561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.
    Pettegrew JW; McClure RJ
    Expert Rev Neurother; 2002 Sep; 2(5):647-54. PubMed ID: 19810980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls.
    Kanfer JN; Pettegrew JW; Moossy J; McCartney DG
    Neurochem Res; 1993 Mar; 18(3):331-4. PubMed ID: 8386814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylethanolamine--the major constituent of the phosphomonoester peak observed by 31P-NMR on developing dog brain.
    Gyulai L; Bolinger L; Leigh JS; Barlow C; Chance B
    FEBS Lett; 1984 Dec; 178(1):137-42. PubMed ID: 6500057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alzheimer's disease: imaging with NMR].
    Soetaert G; Steinling M; Leys D; Gaudet Y; Fauquette A; Petit H
    Acta Neurol Belg; 1989; 89(3-4):246-8. PubMed ID: 2516972
    [No Abstract]   [Full Text] [Related]  

  • 38. Magnetic resonance spectroscopic changes in Alzheimer's disease.
    Pettegrew JW; Klunk WE; Panchalingam K; McClure RJ; Stanley JA
    Ann N Y Acad Sci; 1997 Sep; 826():282-306. PubMed ID: 9329700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal aging and Alzheimer's disease: growing problems.
    Terry RD
    Monogr Pathol; 1990; (32):41-54. PubMed ID: 2192279
    [No Abstract]   [Full Text] [Related]  

  • 40. 31P-NMR determination of phosphomonoesters in relation to phospholipid biosynthesis in testis of the rat at different ages.
    Van der Grond J; Dijkstra G; Roelofsen B; Mali WP
    Biochim Biophys Acta; 1991 May; 1074(1):189-94. PubMed ID: 2043669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.